本文選題：肝細胞肝癌　切入點：肝內(nèi)膽管細胞癌　出處：《山西醫(yī)科大學》2015年碩士論文　論文類型：學位論文

【摘要】：目的:探討三種肝癌分別為肝細胞肝癌和肝內(nèi)膽管細胞癌和結(jié)節(jié)性肝硬化中GPC3、AFP的表達并且比較GPC3、AFP在肝三種肝癌中表達的差異。方法:通過對總共92例患者的分別比較50例原發(fā)性肝細胞肝癌、20例肝內(nèi)膽管細胞癌、22例結(jié)節(jié)性肝硬化的細胞,采用免疫組織化學方法對92例患者手術切除標本中細胞進行GPC3、AFP檢測,檢測GPC3在三種肝癌不同時期和分化的陽性表達情況,比較GPC3、AFP在三種肝癌中表達的差異。結(jié)果:肝細胞肝癌的細胞中GPC3特異性表達且具有敏感性,敏感性分別為84.0%、97.7%,與其余兩種肝癌中GPC3的表達相比,兩者差異有統(tǒng)計學意義(P0.05)。肝細胞肝癌中細胞GPC3蛋白的表達與患者各個方面的差異無統(tǒng)計學意義(P0.05)。在三種分期的肝細胞肝癌中GPC3的陽性率分別為82.4%、84.9%,均明顯高于肝細胞肝癌中AFP蛋白的表達,兩者相比較差異具有統(tǒng)計學意義(P0.05)。肝細胞肝癌中的GPC3和AFP兩者聯(lián)合,就能檢測并且診斷極早期+早期、中期+進展期肝細胞肝癌,檢測和診斷的敏感性提高為88.2%、87.8%。三種不同程度分化的肝細胞肝癌中的GPC3蛋白的陽性率分別為75.0%、85.0%、81.8%,均明顯高于肝細胞肝癌中AFP這種蛋白的表達,差異具有統(tǒng)計學意義(P0.05)。三種分化程度的肝細胞肝癌中GPC3和AFP兩者聯(lián)合檢測可將診斷陽性率的敏感性提高為75.0%、90.0%、90.9%。GPC3肝內(nèi)膽管細胞癌各個分期相比,各種分期的肝內(nèi)膽管細胞癌中的GPC3陽性率分別為0%、6.25%,與肝內(nèi)膽管細胞癌中AFP蛋白的表達相比,無明顯統(tǒng)計學差異(P0.05)。不同分化程度的肝細胞肝癌中GPC3的陽性率分別為25.0%、0%、0%,與肝內(nèi)膽管細胞癌中AFP蛋白的表達相比無明顯統(tǒng)計學差異(P0.05)。結(jié)論:肝細胞肝癌中細胞中GPC3高表達并且可能參與肝細胞肝癌的產(chǎn)生和進展。GPC3高表達于肝細胞肝癌組織中,對早期肝細胞肝癌診斷的重要提示作用,對于區(qū)分良性及惡性早期占位性病變重要提示作用。
[Abstract]:Objective: to investigate the expression of GPC3P AFP in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (HCC) and nodular cirrhosis (LC) and to compare the difference of GPC3 AFP expression in hepatocarcinoma. Methods: a total of 92 patients were enrolled in this study. The cells of 20 cases of intrahepatic cholangiocarcinoma and 22 cases of nodular liver cirrhosis were compared in 50 cases of primary hepatocellular carcinoma (HCC) and 20 cases of intrahepatic cholangiocarcinoma. Immunohistochemical method was used to detect the expression of GPC3 in the cells of 92 patients undergoing surgical resection, and the positive expression of GPC3AFP was detected at different stages and differentiation of three kinds of liver cancer. Results: the expression of GPC3 in HCC cells was specific and sensitive, and the sensitivity was 84.0 and 97.7, respectively, compared with the expression of GPC3 in the other two types of HCC. The difference was statistically significant (P 0.05). There was no significant difference between the expression of GPC3 protein in hepatocellular carcinoma and all aspects of the patients. The positive rates of GPC3 in the three stages of HCC were 82.4% and 84.9%, respectively, which were significantly higher than those in the fine liver tissue. Expression of AFP protein in hepatocellular carcinoma, The combination of GPC3 and AFP in hepatocellular carcinoma can detect and diagnose very early and middle stage advanced hepatocellular carcinoma. The sensitivity of detection and diagnosis was increased to 87.8%. The positive rates of GPC3 protein in the three kinds of differentiated hepatocellular carcinoma were 75.0% and 85.0%, respectively, which were significantly higher than the expression of AFP protein in hepatocellular carcinoma (HCC). The difference was statistically significant (P 0.05). The combined detection of GPC3 and AFP in three kinds of hepatocellular carcinoma with different degrees of differentiation could increase the sensitivity of the positive rate to 75.0% and 90.9%, compared with each stage of intrahepatic cholangiocarcinoma. The positive rates of GPC3 in various stages of intrahepatic cholangiocarcinoma were 0 and 6.25, respectively, compared with the expression of AFP protein in intrahepatic cholangiocarcinoma. The positive rates of GPC3 in hepatocellular carcinoma with different differentiation degrees were 25.0 and 25.0, respectively. There was no significant difference between the expression of AFP protein and that of intrahepatic cholangiocarcinoma. Conclusion: the expression of GPC3 in hepatocellular carcinoma is not significantly different from that in intrahepatic cholangiocarcinoma. Conclusion: there is no significant difference in the expression of AFP protein between HCC and HCC. Conclusion: there is no significant difference in the expression of AFP protein between HCC and HCC. High expression and may be involved in the production and progression of hepatocellular carcinoma. GPC3 is highly expressed in hepatocellular carcinoma. It is important to diagnose early hepatocellular carcinoma and to distinguish benign and malignant early occupying lesions.
【學位授予單位】：山西醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2015
【分類號】：R735.7

【相似文獻】

相關期刊論文 前10條

1 朱立新,耿小平;肝細胞肝癌術后復發(fā)的危險因素、預防及治療[J];肝膽外科雜志;2000年06期

2 季偉,王慧芬;乙型肝炎病毒感染合并肝細胞肝癌153例臨床分析[J];中華肝臟病雜志;2001年06期

3 陳孝平;張志偉;楊甲梅;沈鋒;;肝細胞肝癌外科治療方法的選擇[J];中華普通外科學文獻(電子版);2008年06期

4 董碩;謝廣茹;吳雄志;;男性肝細胞肝癌術后預后因素分析[J];中國腫瘤臨床;2008年08期

5 陳孝平;張志偉;楊甲梅;沈鋒;;肝細胞肝癌外科治療方法的選擇[J];中華普通外科學文獻(電子版);2009年02期

6 郭洪生;杜智;高英堂;薛春祥;張勤;朱爭艷;王偉麗;;磷脂酰肌醇蛋白聚糖3在肝細胞肝癌中的表達及意義[J];中國腫瘤臨床;2009年08期

7 陳孝平;張志偉;楊甲梅;沈鋒;;肝細胞肝癌外科治療方法的選擇[J];中華普通外科學文獻(電子版);2010年01期

8 徐霽;;多齒針大劑量乙醇消融治療直徑5.0cm以內(nèi)的肝細胞肝癌[J];國際醫(yī)學放射學雜志;2010年01期

9 張國強;楊定華;李相z，

本文編號：1617558